O
CELG

OrbiMed’s Celgene Corp CELG Stock Holding History

OrbiMed’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-295,000
Closed -$27.8M – 145
2019
Q1 		$27.8M Sell
295,000
-2,961,700
-91% -$259M 0.43% 59
2018
Q4 		$209M Buy
3,256,700
+792,850
+32% +$58.5M 3.86% 4
2018
Q3 		$220M Sell
2,463,850
-106,800
-4% -$9.44M 2.66% 8
2018
Q2 		$204M Sell
2,570,650
-63,600
-2% -$5.28M 2.44% 9
2018
Q1 		$235M Sell
2,634,250
-428,600
-14% -$41.1M 2.91% 7
2017
Q4 		$320M Sell
3,062,850
-289,127
-9% -$32.6M 4.04% 4
2017
Q3 		$489M Sell
3,351,977
-73,800
-2% -$10.1M 4.67% 3
2017
Q2 		$445M Buy
3,425,777
+293,600
+9% +$36M 4.66% 2
2017
Q1 		$390M Buy
3,132,177
+25,400
+0.8% +$3.04M 4.42% 3
2016
Q4 		$360M Buy
3,106,777
+158,200
+5% +$17.6M 4.58% 3
2016
Q3 		$308M Buy
2,948,577
+543,900
+23% +$58.9M 3.51% 5
2016
Q2 		$237M Sell
2,404,677
-1,369,400
-36% -$142M 2.47% 10
2016
Q1 		$378M Buy
3,774,077
+108,627
+3% +$11.2M 3.97% 8
2015
Q4 		$439M Buy
3,665,450
+72,450
+2% +$8.38M 3.98% 7
2015
Q3 		$389M Sell
3,593,000
-233,000
-6% -$28.9M 3.92% 6
2015
Q2 		$443M Buy
3,826,000
+654,000
+21% +$74.8M 3.7% 6
2015
Q1 		$366M Sell
3,172,000
-485,600
-13% -$58M 3.12% 5
2014
Q4 		$409M Buy
3,657,600
+329,600
+10% +$34.8M 3.91% 4
2014
Q3 		$315M Buy
3,328,000
+673,000
+25% +$60.7M 3.29% 9
2014
Q2 		$228M Sell
2,655,000
-87,800
-3% -$6.68M 2.68% 12
2014
Q1 		$191M Sell
2,742,800
-771,400
-22% -$61.1M 2.35% 12
2013
Q4 		$297M Buy
3,514,200
+900,200
+34% +$71.2M 4.36% 3
2013
Q3 		$201M Buy
2,614,000
+141,200
+6% +$9.9M 3.59% 6
2013
Q2 		$145M Buy
+2,472,800
New +$149M 3.07% 8

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

OrbiMed's CELG Position: Q2 2019 in Review

OrbiMed sold out of Celgene Corp (CELG) in Q2 2019, closing a stake of 295,000 shares — an estimated $27.8M sold.

OrbiMed first reported a position in CELG in Q2 2013 and held it in 24 quarters. The position peaked at $489M in Q3 2017. 1,288 funds tracked by Wall St. Rank hold CELG as of Q2 2019.

  • OrbiMed reported no remaining Celgene Corp position as of Q2 2019 after selling out during the quarter.
  • OrbiMed sold 295,000 Celgene Corp shares in Q2 2019, an estimated $27.8M.
  • OrbiMed first reported a position in Celgene Corp in Q2 2013 and held it in 24 quarters.
  • OrbiMed's Celgene Corp position peaked at $489M in Q3 2017.
  • 1,288 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2019.

Based on OrbiMed's 13F filing for Q2 2019, filed 14 Aug 2019.